VISCHER advises the investors in a Series C round of CHF 18 million (USD 20.4 million) led by Edmond de Rothschild Investment Partners (EdRIP) in GenKyoTex SA in Geneva. New investors in the company include Vesalius Biocapital Partners and MP Healthcare Venture Management. Existing investors, Eclosion, SEFTI SGAM and Fondation d?Aide aux Entreprises (FAE) also participate in the financing. The company is the NOX enzyme specialist developing a compound for the treatment of diabetic nephropathy. VISCHER AG led by Matthias Staehelin (Partner) with Laura Rey (Associate) advises the investors.